Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

BACKGROUND: To determine safety and efficacy of single cycle induction treatment with cisplatin/docetaxel and durvalumab/tremelimumab in stage III-IVB head and neck cancer. METHODS: Patients received a single cycle of cisplatin 30 mg/m² on days 1–3 and docetaxel 75 mg/m² on day 1 combined with durva...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Hecht, Markus, Gostian, Antoniu Oreste, Eckstein, Markus, Rutzner, Sandra, von der Grün, Jens, Illmer, Thomas, Hautmann, Matthias G, Klautke, Gunther, Laban, Simon, Brunner, Thomas, Hinke, Axel, Becker, Ina, Frey, Benjamin, Semrau, Sabine, Geppert, Carol I, Hartmann, Arndt, Balermpas, Panagiotis, Budach, Wilfried, Gaipl, Udo S, Iro, Heinrich, Fietkau, Rainer
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539609/
https://ncbi.nlm.nih.gov/pubmed/33023982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001378
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados